Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

Zoe Moodie*, One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes, Jack Heptinstall, Faatima Laher Omar, Kristen Cohen, Stephen C. De Rosa, Lu Zhang, Nicole L. Yates, Marcella Sarzotti-Kelsoe, Kelly E. Seaton, Fatima Laher, Linda Gail Bekker, Mookho Malahleha, Craig Innes, Sheetal Kassim, Nivashnee NaickerVaneshree Govender, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Erica Lazarus, Maphoshane Nchabeleng, Amy M. Ward, William Brumskine, Thozama Dubula, April K. Randhawa, Nicole Grunenberg, John Hural, Jia Jin Kee, David Benkeser, Yutong Jin, Lindsay N. Carpp, Mary Allen, Patricia D’Souza, James Tartaglia, Carlos A. DiazGranados, Marguerite Koutsoukos, Peter B. Gilbert, James G. Kublin, Lawrence Corey, Erica Andersen-Nissen, Glenda E. Gray, Georgia D. Tomaras, M. Juliana McElrath

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk'. Together they form a unique fingerprint.

Medicine & Life Sciences